NSCL NSCL23

Size: px

Start display at page:

Download "NSCL NSCL23"

寮伊
5 years ago
Views:

1 (NCCN) R ;R , 90 %,,, ( FDA),,, NSCL21 (A HCPR), ( ), (NCCN) ( I2EL2 CA P) :610041, ( :,E2mail com. cn)

2 NSCL NSCL23

3 NSCL NSCL25

4 NSCL NSCL27

5 NSCL NSCL29

6 NSCL NSCL211

7 NSCL NSCL213

8 NSCL NSCL NSCL216

9 , 3. 3, 3. 4 N1 N2 (N2 3 ) , ( ), 4 ( RT) (BSC),,, 5. 4 (25 % 35 %), (4 6 ), (8 10 ),1 (30 % 40 %) 2 (10 % 15 %) ( 3 4), , ( ) 4. 2, 4. 3, 4. 4,,,, 4. 5, 4. 6 CT,, CT X, /,,, ( 4 10 MV ) ( 15 MeV, 18 MeV ) ( GTV) /, ( PS ) : Erlotinib PS 0 2, ,, , (BSC), 6 12,1 1 ( 10 % 15 %) : /, PS = PS = ,, Erlotinib

10 , Erlotinib,, Erlotinib TNM ( 1) 1 TNM TNM 0 A B A B A B T1N0 M0 T2N0 M0 T1N1 M0 T2N1 M0 T3N0 M0 T1N2 M0 T2N2 M0 T3N1 M0 T3N2 M0 T4N0 M0 T4N1 M0 T4N2 M0 T1N3 M0 T2N3 M0 T3N3 M0 T4N3 M0 T, N,M1 : TxN0 M TNM ( 2) 8 ( G) Gx : ; G1 : ; G2 : ; G3 : ; G4 : :,,, 9. 2 :, ( ),,, 9. 3 :,,,,, ( T) 2 TNM TX :,, T0 : Tis : T1 : 3 cm,, 3 ( ) T2 : > 3 cm, 2 cm, T3 : : ( ),,, ;, < 2 cm, ; T4 : :,,,,,, ; ; 3 3 (N) Nx : N0 : N1 : /,, N2 : N3 :,, (M) Mx : M0 : M1 : [ ( ) ] 3 :, T1 3 3 :,,, (VA TS),, T1 T2 T MRI

11 / ( T122,N1 ), B ( T4, N021 ) 10. 5,, Erlotinib 11 NCCN ,NCCN A,NCCN B,NCCN, NCCN A (91 800, ), (88 400, ), 14 % 5, 85 %,, 226,, 85 %,,,,,,, (,, ), (CT), 80 %,NCCN CT (ACRIN) A , : ( ) 80 % 85 %, 3 : ( ),,,, ( Eastern Cooperative Oncology Group 0,1 2), ( 5 %),, (p53),k2ras,,, 15,, , (AJ CC) 3 % 4 %,,,, ( ) 1, TNM 2, : T1 N0 M0 ( A) T2 N0 M0 ( 13 B) : T1 N0 M0 T2 N0 M A ( T1 N1 M0 ) B ( T2 N1 M0 T3 N0 M0 ) A T3 N0 M0 T2 N1 M0 B, B

12 343 T4 M1 ( 2) : T4 ; ( ) T4 ;, ( ), M1, (, ) M1, 1 40 %,,, :???, 16,10 %,20 %,15 % A, 15 % B,40 % 5 : A 67 %, B 57 % ; A 55 %, B 38 % 39 % ; A 23 % 25 %, B 3 % 7 % ; 1 %,,, (ACOSO G), N0 ( ) N1 ( / ) k2ras ( BR210 ), IAL T ( International Adjuvant L ung Trial), A, 5 %, (BLO T) ( ), B A ( T3 N1 M0 ) 3 A 3,, A B, ( ),,, (, ),, X CT ( ) (CBC) (LD H), 10 17,,,,, T3 CT, CT, T1 T2, NCCN ( 2B), CT T1 T2,,, A B ( T4,N021 ),, ( PET) ( T122 N0, 2B), CT (N1, N2 N3, ), PET

13 344 CT PET, 2 CT 40 % 65 %, 45 % 90 % Seely CT ( T1 ), A, 21 % N2 N3, CT 43 %, 92 % Dillemans, CT T1, 16 % N2 CT N2 69 % 71 % CT N2 CT (89 % 71 %) CT, CT,Arita 90, 16 % CT, N2 N3 PET, CT,, Chin PET 78 %, 81 %, 89 % Kerstine PET CT N2 N3, PET CT (81 % 76 %), PET, ( T122 N0 ) ( 2B) ( T122 N0 ) PET, (MRI), B, DCLO, A B ( T2 N1 ), ( T122 N1 ), ( N2 ),,, T122 N2,, T122 N2, T122 N2, MRI B ( T3 N0 ) A B B ( T3 N0 ) ( ), B ( T3 N0 ) A ( T3 N1 ) B ( T4 N021 ), (,, ) ( T324 N021 ), ;,,,,, ( T324 N021 ), ( ), ( 3) ( T3 N021 ),, ; ( T3 N021 ), 5 40 % 2 50 % 70 % A ( T123 N2 ), ( FNA) MRI PET ( ),, ( T123 N2 ), MRI PET ( ),, T123 N2,

14 345 T123 N2, ( Naruke T4 5 8 %,,, ( 2B) T4 N021, T123 N3 ( ) N3,, PET MRI,, ( 1) T4 N223 N3 N2,, B ( T4 N021 ),, ( 1), 2B) N2, ( ) B, 5 10 % 20 %,, : N021 T4 ( T4 ) ; ( T, N3 ), ; T4 N223 2B M1 (, ; B T4 N021 ( ), T N, 33 % ) A,, CT,,, 3 ( ),, 19 T1 N0 N0 N1, T2, N1 (L ung Cancer St udy Group,1986) T4, 90 % 95 %,, ( ),, 1998 ( POR T Meta2analysis Trialist s Group,1998), : 60, ;, T N 60, ;,,,95 % M1,, ; ( ) ; /, IAL T, ( ) B ( ), MRI PET, PET,,,,,,

15 346 N2 ( ) ( 2B) ( 2B) E3590, 5 19 %, NCCN B, N2 A N021 B,, ;, T3 N021 N021,, N2, - -, ( N3 ), 20 X , 3 6 1, 1 CT X, 1,, ;,, 3 : ( ), ( PD T) (SVC), PD T, ( 2B),, M1 ( ),, 3 1, T123,,, ( 1 2 ) CT 25 % 1, 4 6 ( 2B), ( PS) 0 2,, 10 %, / 0 1 2,, PS 3 4,

PowerPoint 演示文稿

PowerPoint 演示文稿卢简言福建医科大学医学技术与工程学院影像系放射诊断学教研室福建医科大学附属协和医院放射科一乳房的解剖乳房外形 :1 圆丘型 2 半球型 3 圆锥型 4 下垂型临床上乳房分区 : 内上内下外上外下中央区 ( 乳晕 ) 乳房构成 : 皮肤